Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Feldman

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Journal of Cutaneous Medicine and Surgery|September 1, 2018
A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus TreatmentTeresa Ro, Rechelle Z Tull, Leah A Cardwell, et al.
Dermatology and Therapy|May 11, 2024
Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in ChinaYehong Kuang, Yuzhen Li, Chengzhi Lv, et al.
Journal for Immunotherapy of Cancer|September 15, 2020
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case reportLiora Schultz, Shabnum Patel, Kara Lynn Davis, et al.
International Journal of Sports Physical Therapy|May 5, 2026
Countermovement Jump and Quantitative Electroencephalography Assessment in Division I Football Athletes: An Exploratory Neurophysiological Study of Return‑to‑Play ReadinessRobert E Mangine, Bradley T Jacobs, James A Tersak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptorJames N Kochenderfer, Mark E Dudley, Sadik H Kassim, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Cytotherapy|November 5, 2025
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Cutaneous Medicine and Surgery|September 1, 2018
A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus TreatmentTeresa Ro, Rechelle Z Tull, Leah A Cardwell, et al.
Dermatology and Therapy|May 11, 2024
Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in ChinaYehong Kuang, Yuzhen Li, Chengzhi Lv, et al.
Journal for Immunotherapy of Cancer|September 15, 2020
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case reportLiora Schultz, Shabnum Patel, Kara Lynn Davis, et al.
International Journal of Sports Physical Therapy|May 5, 2026
Countermovement Jump and Quantitative Electroencephalography Assessment in Division I Football Athletes: An Exploratory Neurophysiological Study of Return‑to‑Play ReadinessRobert E Mangine, Bradley T Jacobs, James A Tersak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptorJames N Kochenderfer, Mark E Dudley, Sadik H Kassim, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Cytotherapy|November 5, 2025
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Pageof 7